Using 4-day MTS cell viability assays we tested the in vitro anti-leukemic potential of Salirasib (RAS localization inhibitor), Vemurafenib (BRAF inhibitor), Sorafenib (pan-kinase inhibitor), Trametinib, Selumetinib and MEK162 (MEK inhibitors) and Temsirolimus (mTOR inhibitor) against RAS-mutant MLL-rearranged ALL cell line KOPN8, and the RAS-wildtype MLL-rearranged cell lines SEM and RS4;11. Here, BRAF is linked to acute lymphoblastic leukemia.